Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Leading US Clinical Labs and Cancer Centers Adopt NanoString's Breast Cancer Assay

Published: Thursday, December 12, 2013
Last Updated: Thursday, December 12, 2013
Bookmark and Share
Diagnostic laboratories ARUP Laboratories, LabCorp, and Quest Diagnostics to offer the Prosigna breast cancer assay.

NanoString Technologies, Inc. announce nationwide availability of the Prosigna™ Breast Cancer Prognostic Gene Signature Assay beginning in the first quarter of 2014. Premier national diagnostic laboratories ARUP Laboratories, Laboratory Corporation of America® Holdings, and Quest Diagnostics have chosen to add the Prosigna Assay to their comprehensive suites of breast cancer diagnostic tests, providing patients treated throughout the U.S. with timely access to a genomic assay that assesses a tumor’s underlying biology and risk of distant recurrence. NanoString Technologies also announced that laboratories at the University of Alabama at Birmingham Comprehensive Cancer Center and University of North Carolina Lineberger Comprehensive Cancer Center will be among the initial wave of facilities to offer the Prosigna Assay in 2014.

NanoString will showcase the Prosigna Assay at booth #209 during the annual San Antonio Breast Cancer Symposium, December 11th -13th 2013, the leading international gathering of academic and community physicians specializing in breast cancer research and treatment.

National diagnostic laboratories adopting the Prosigna Assay commented on the new offering:

“This is the next generation of diagnostics, which embraces both the molecular and anatomic features of a tumor to provide a more accurate estimate of risk,” said Philip Bernard, MD, ARUP Laboratories Medical Director and Associate Professor in the Department of Pathology at the University of Utah.

“LabCorp is pleased to be among the first laboratories to offer the Prosigna assay,” stated Mark Brecher, MD, LabCorp Chief Medical Officer. “Prosigna provides physicians and their patients a new and important diagnostic tool, in conjunction with other clinical and pathological factors, to help monitor and treat breast cancer recurrence.”

“We are pleased to form this relationship with NanoString”, said Gerald LaFlamme, Quest General Manager, Oncology business. “The Prosigna Assay will extend our capabilities in breast cancer and provide an important new option for women.”

Brad Gray, President and Chief Executive Officer of NanoString Technologies commented on the national diagnostic laboratory and cancer center adoption of Prosigna: “We look forward to working closely with our clinical laboratory and cancer center partners, and believe these collaborations will provide a solid foothold in the breast cancer genomic assay market. These laboratories collectively serve the pathology testing needs of a substantial portion of breast cancer patients throughout the U.S. In the months ahead, we plan to coordinate closely with these laboratories so they can successfully provide locally accessible and clinically important insights from breast tumor genomics.”

Financial terms of the transactions were not disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cigna to Cover NanoString's Prosigna® Breast Cancer Assay
NanoString Technologies has announced that Cigna has issued a positive Medical Coverage Policy decision for the Prosigna® Breast Cancer Gene Signature Assay.
Friday, May 27, 2016
NanoString Technologies and Merck Expand Collaboration
Company has announced collaboration to develop and commercialize novel diagnostic test to predict response to keytruda® (pembrolizumab) Merck's anti-PD-1 therapy.
Friday, March 04, 2016
NanoString, Merck Expand Collaboration
NanoString eligible to receive up to $24 million for technology access and near-term milestones, plus development funding and undisclosed downstream payments.
Tuesday, March 01, 2016
NanoString, Brigham and Women’s Hospital Collaborate
Research collaboration to accelerate translation of genomic discoveries into clinical diagnostics in oncology.
Wednesday, October 08, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
CDC Updates Zika Recommendations
CDC has issued updated Zika recommendations and guidance for healthcare providers with a focus on sexual transmission.
Review of the Analysis of Haemoglobin A1c for Diabetes Diagnostics
This paper aims to clarify methods, units, quality requirements, reference and cutoff limits for hemoglobin A1c (HbA1c) and ratio of blood glucose/HbA1c on the basis of the results from Finnish quality control surveys by comparing them to the literature.
Colon Cancer Blocked in Mice
Case Western Reserve University Researchers block common type of colon cancer tumour in mice, laying groundwork for human clinical trial.
Drug - Gene 'One-Two' Punch Against Cancer
Researchers identify gene-drug combinations that, together, target and kill cancer cells while not targeting healthy cells.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
72% Rise in Metastatic Prostate Cancer
Over the 2003-2013 period metastatic cancer has increased by an average of 72%, this could be caused by lax screening, more aggressive disease or both.
Lab-Tested Diagnosis Needed When Treating Persistent Diarrhea
New PCR multiplex method makes lab testing more effective.
Biomarker for Multiple Sclerosis Detection Discovered
Winthrop-University Hospital researchers discover biomarker for multiple sclerosis detection.
Scientists Link Bipolar Disorder to Unexpected Brain Region
Researchers from The Scripps Research Institute have found that gene within the brain’s striatum could be linked to biopolar disorder.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!